Presymptomatic screening to detect early-stage cancer reduces cancer-relate
d mortality and treatment-related morbidity. Identifying a new class of can
cer-associated serum proteins and validating sensitive and specific predict
ive assays would expand the current clinical capabilities for early cancer
detection and diagnosis, and further reduce cancer mortality.